Audio is streamed directly from the publisher (podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Newt talks with Jonathan Dickinson, CEO and José Inzunza, Chief Medical Officer, Co-Founders of Ambio Life Sciences, a global leader in integrative Ibogaine treatment. They discuss the potential of Ibogaine as a therapy for post-traumatic stress disorder, opioid addiction, and depression. Ibogaine is classified as a Schedule I controlled substance by the U.S. Drug Enforcement Agency and is primarily administered in treatment facilities outside the U.S., such as in Mexico and Canada. They talk about their experiences administering Ibogaine and insights into its therapeutic effects, particularly the ability to mitigate opioid withdrawal symptoms and improve neurological health. They also highlight the importance of patient preparation and the need for ongoing support post-treatment to prevent relapse. Ambio Life Sciences collaborated with Stanford University and their pioneering clinical program for neurodegenerative diseases to study conditions like Parkinson's and multiple sclerosis. Their discussion underscores Ibogaine's potential to revolutionize addiction treatment and neurological health.
See omnystudio.com/listener for privacy information.